Cytogen Corporation Release: Combination Of High Dose QUADRAMET(R) And Chemotherapy Shows Promise For Treatment Of High-Risk Acute Myeloid Leukemia

PRINCETON, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO - News) today announced the publication of new data relating to the Company’s QUADRAMET® (samarium Sm-153 lexidronam injection) product. The publication, “Marrow irradiation with high-dose 153 Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia” by Vilmarie Rodriguez, M.D., a Pediatric Oncologist at The Mayo Clinic in Rochester, Minnesota, appears in a recent issue of the peer-reviewed journal Leukemia & Lymphoma (Leuk Lymphoma. 2006 Aug;47(8):1583-92).